Why Dyadic International, Inc.’s (DYAI) Stock Is Up 5.44%
As of Wednesday, July 22, Dyadic International, Inc.’s DYAI share price has surged by 5.44%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases; and collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Commentary & Analysis
Why Dyadic International, Inc.’s (DYAI) Stock Is Down 10.06%
As of Tuesday, February 18, Dyadic International, Inc.’s DYAI share price has dipped by 10.06%, which has investors questioning if this is right time to buy.Omar Beirat
Is Dyadic International Stock (DYAI) a Good Investment?
Learn more about Dyadic International, Inc.’s (DYAI) stock grades for Value, Growth, Momentum, Estimate Revisions and Quality and determine whether this Biotechnology & Medical Research stock meets your investment needs.
Jenna Brashear
Financial Summary
| Share Statistics | DYAI | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $19.0 | $282.4 | 9% |
|
| Shares Out (Mil) | 36.4 | 54.0 | 41% |
|
| Institutional Ownership | 34.1% | 93.1% | 14% |
|
| Float (Mil) | 27.5 | 42.2 | 34% |
|
| Beta | 1.02 | 0.94 | 62% |
|
| Avg Daily Volume (000s) | 188 | 482 | 45% |
|
| Price Change (52-week) |
(45.6%) | 59.9% | 17% |
|
| Growth | DYAI | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 14.1% | 14.1% | 71% |
|
| Net Income (5yr) | 4.5% | (10.1%) | 46% |
|
| EPS (5yr) | 7.8% | 15.9% | 43 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.3%) | (15.6%) | 50% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | DYAI | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $4 | $37 | 5% |
|
| Net Income (TTM) (Mil) | ($8) | ($43) | 31% |
|
| EPS (TTM) | ($0.213) | ($1.500) | 33% |
|
| Operating Cash Flow (TTM) (Mil) | ($7) | ($31) | 22% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $5 | $4 | 24% |
|
| Enterprise Value (Q1) (Mil) | $27 | $190 | 13% |
|
| Valuation | DYAI | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.84 | na |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | DYAI | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 16.2% | 66.9% | 16% |
|
| Net Margin | (200.5%) | (74.2%) | 5% |
|
| ROA | (103.9%) | (47.7%) | 5% |
|
| ROE | 522.6% | (55.0%) | 100% |
|
| Liabilities to Assets | 136.5% | 29.8% | 97% |
|
| F-Score | 2 | 3 | 7% |
|
Dyadic International, Inc. did not pass any screens on 9/4/2026.
